remlarsen
Nucleic acidexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2015 (NCT02603224)
Timeline
Indications
Studied for
Mechanism of action
- MicroRNA 29Supplementation
MicroRNA 29 supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594491 ↗
Also known as
- mrg-201
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03601052 | Phase 2 | Jul 9, 2018 | miRagen Therapeutics, Inc. |
| NCT02603224 | Phase 1 | Nov 1, 2015 | miRagen Therapeutics, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| miRagen Therapeutics, Inc. | For profit | 2 | 2 | 2 | 2015 |
1 organizations
Page 1 / 1